- Home
- VRTX vs CRWD Comparison
VRTX vs CRWD Comparison
Compare VRTX & CRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- CRWD
- Stock Information
- Founded
- VRTX 1989
- CRWD 2011
- Country
- VRTX United States
- CRWD United States
- Employees
- VRTX N/A
- CRWD N/A
- Industry
- VRTX EDP Services
- CRWD EDP Services
- Sector
- VRTX Technology
- CRWD Technology
- Exchange
- VRTX Nasdaq
- CRWD Nasdaq
- Market Cap
- VRTX 104.8B
- CRWD 85.9B
- IPO Year
- VRTX 1991
- CRWD 2019
- Fundamental
- Price
- VRTX $422.00
- CRWD $357.00
- Analyst Decision
- VRTX Buy
- CRWD Buy
- Analyst Count
- VRTX 30
- CRWD 45
- Target Price
- VRTX $503.92
- CRWD $367.41
- AVG Volume (30 Days)
- VRTX 2.1M
- CRWD 3.0M
- Earning Date
- VRTX 02-03-2025
- CRWD 03-04-2025
- Dividend Yield
- VRTX N/A
- CRWD N/A
- EPS Growth
- VRTX N/A
- CRWD N/A
- EPS
- VRTX N/A
- CRWD 0.51
- Revenue
- VRTX $10,625,800,000.00
- CRWD $3,740,421,000.00
- Revenue This Year
- VRTX $12.56
- CRWD $31.14
- Revenue Next Year
- VRTX $8.34
- CRWD $21.31
- P/E Ratio
- VRTX N/A
- CRWD $693.97
- Revenue Growth
- VRTX 10.06
- CRWD 31.35
- 52 Week Low
- VRTX $377.85
- CRWD $200.81
- 52 Week High
- VRTX $519.88
- CRWD $398.33
- Technical
- Relative Strength Index (RSI)
- VRTX 48.34
- CRWD 51.08
- Support Level
- VRTX $397.25
- CRWD $335.55
- Resistance Level
- VRTX $425.49
- CRWD $370.37
- Average True Range (ATR)
- VRTX 8.24
- CRWD 11.97
- MACD
- VRTX 3.71
- CRWD -0.35
- Stochastic Oscillator
- VRTX 79.84
- CRWD 60.59
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.